Discover the winners of the Start-up Slams

More than 50 start-ups applied for the MedFIT Start-up Slams competition, hoping to present their innovation to an audience of potential investors and industrial and academic partners. 17 of them were selected before the event by an international jury chaired by Johnson & Johnson Innovation, sponsor of the competition.

4 prizes were awarded:

2 Audience Prizes:

    • Defymed, with ExOlin, device allowing the physiological administration of drugs via a simple subcutaneous injections using a conventional injection device such as a serynge.



« The Start-ups Slams were a logical answer to our needs: Search funds for the development of our technologies and take the opportunity to present our brand new medical device.” Defymed

  • Miravas, with Vbox a unique medical device that combines two endothermal techniques (steam and segmental radiofrequency) to treat outpatient venous disease as an alternative to surgery.

“We are very glad that the audience vote for us. It means they know who we are and what we do. It’s exactly why we applied: To make people known our product, to boost the visibility of our company at a European scale.” Miravas

A Special Jury Prize:

  • VerapidoDERMAJECT®, an intradermal injection device for highly standardized skin injections (intracutaneous, Mantoux) of all intradermal drugs and fluids.

“The Start-up Slams contest is the perfect stage to gain visibility and find partners and investors. We were absolutely thrilled by two highly intense days fully packed with high potential personal meetings and great plenary sessions and tracks with deep and relevant industry insights.” Verapido  


The Grand Jury prize :

  • Ablacare, with a device for the treatment of PolyCystic Ovary Syndrome (PCOS)-related infertility, based on an effective and demonstrated surgical predicate and an access and delivery path routinely used by fertility physicians.

“We are proud to have been awarded the MedFIT Most innovative start-up Grand Jury Prize. At AblaCare we are dedicated to providing millions of couples around the world facing fertility issues with a more human and effective solution. We were very excited to have been selected to present our mission to the medtech community present in Strasbourg.” AblaCare